Search the Newsreel

Rock Springs Capital Management LP Makes New $2.25 Million Investment in Dianthus Therapeutics, Inc. $DNTH

Rock Springs Capital Management LP has made a new $2.25 million investment in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by acquiring 26,757 shares. Despite a positive analyst outlook with a "Moderate Buy" rating and an average price target of $117.82, company insiders have sold approximately $7.99 …

BlackRock, Inc. (DNTH) discloses 6.4% Dianthus Therapeutics stake in 13G/A

BlackRock, Inc. has filed an Amendment No. 1 to a Schedule 13G, disclosing a beneficial ownership of 6.4% in Dianthus Therapeutics Inc. common stock, amounting to 3,504,166 shares as of June 30, 2026. BlackRock holds sole voting power over 3,433,718 shares and sole dispositive …

DNTH News | DIANTHUS THERAPEUTICS INC (NASDAQ:DNTH)

Octagon Capital Advisors LP Has $163.36 Million Position in Dianthus Therapeutics, Inc. $DNTH

Octagon Capital Advisors LP reduced its stake in Dianthus Therapeutics, Inc. by 19.4% in the first quarter, yet it remains its largest holding, valued at $163.36 million. Despite insider selling, institutional ownership in DNTH is significant, with several firms increasing their positions. Analysts maintain …

Dianthus Therapeutics Inc (DNTH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides details on Dianthus Therapeutics Inc's (DNTH) revenue breakdown. It indicates that relevant data for business segments and profit contribution have not yet been disclosed by the company for FY2025, FY2025Q4, and FY2025Q3. The company only reports a United States revenue proportion …

Dianthus Therapeutics Inc (DNTH) Cash Flow

This article provides a detailed cash flow statement for Dianthus Therapeutics Inc (DNTH), including quarterly and annual data for operating, investing, and financing activities. It also defines key cash flow metrics and answers frequently asked questions regarding DNTH's cash flow performance, such as operating …

Dianthus Therapeutics, Inc. $DNTH Shares Bought by SummitTX Capital L.P.

Spruce Street Capital LP Raises Stock Holdings in Dianthus Therapeutics, Inc. $DNTH

Spruce Street Capital LP significantly increased its stake in Dianthus Therapeutics (NASDAQ:DNTH) by 25.5% in the first quarter of 2026, holding 373,274 shares valued at $31.3 million. Despite recent insider sales totaling about $8.0 million, analysts maintain a "Moderate Buy" rating with an average …

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of "Moderate Buy" from Analysts

Dianthus Therapeutics (NASDAQ:DNTH) has an average "Moderate Buy" rating from 14 analysts, with a 12-month average price target of $117.82. The stock is currently trading near its 52-week high of $107.99, having risen significantly from its 52-week low. Despite recent insider selling, the company's …

Walleye Capital LLC Has $12.89 Million Position in Dianthus Therapeutics, Inc. $DNTH

Walleye Capital LLC reduced its stake in Dianthus Therapeutics (NASDAQ:DNTH) by 25.4% in the first quarter, holding 153,585 shares valued at $12.89 million. Despite this, other institutional investors have acquired new positions in the company. Insider selling has also been noted, with SVP Adam …

Dianthus Therapeutics Stock Surges After Initiating Major Phase 3 Clinical Trial

Dianthus Therapeutics (DNTH) stock surged 11% after announcing the initiation of its Phase 3 EMERGE trial for claseprubart to treat generalized myasthenia gravis. The market reacted positively to this major clinical milestone, despite primary results not being expected until the second half of 2028. …

Wedbush Maintains Dianthus Therapeutics (DNTH) Outperform Recommendation

Wedbush has reiterated its Outperform rating for Dianthus Therapeutics (DNTH). This indicates the firm's continued positive outlook on the company's stock performance.

Enterprise value to EBITDA forward of Dianthus Therapeutics, Inc. – FWB:87E

This article provides financial information for Dianthus Therapeutics, Inc. (FWB:87E), specifically focusing on its enterprise value to EBITDA forward metric. The content highlights that market data is provided by ICE Data Services and FactSet, with SEC filings from Quartr. It also mentions that the …

Dianthus Therapeutics, Inc. (DNTH) reports Q1 loss, lags revenue estimates

Dianthus Therapeutics, Inc. (DNTH) reported a Q1 loss, failing to meet revenue estimates. This indicates a challenging quarter for the company financially.

DNTH Stock Pops As Phase 3 EMERGE Trial Kicks Off

Dianthus Therapeutics Inc. (DNTH) stock surged by 10.75% after the company announced the initiation of its global, randomized, placebo-controlled Phase 3 EMERGE trial for its drug candidate claseprubart to treat generalized myasthenia gravis. The trial is expected to deliver primary functional endpoint data in …

Dianthus Therapeutics stock hits 52-week high at 102.38 USD

Dianthus Therapeutics (DNTH) stock has reached a new 52-week high of $102.38, marking a significant 395.74% increase over the past year and a market capitalization of $5.57 billion. This surge reflects investor confidence, driven by strong returns and the initiation of its Phase 3 …